5-Methyl-1,5-diazapentacyclo[10.8.1.02,7.08,21.014,19]henicosa-2(7),8,10,12(21),14,16,18-heptaene | 1538586-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 5-Methyl-1,5-diazapentacyclo[10.8.1.02,7.08,21.014,19]henicosa-2(7),8,10,12(21),14,16,18-heptaene
• 英文别名: 5-methyl-1,5-diazapentacyclo[10.8.1.02,7.08,21.014,19]henicosa-2(7),8,10,12(21),14,16,18-heptaene
• CAS: 1538586-06-9
• 化学式: C₂₀H₂₀N₂
• 分子量: 288.392
• InChiKey: RQBRUGMHSQYCNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  8.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  6,11-二氢-5H-二苯并[b,e]氮杂卓 在 溶剂黄146 、 锌 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 生成 5-Methyl-1,5-diazapentacyclo[10.8.1.02,7.08,21.014,19]henicosa-2(7),8,10,12(21),14,16,18-heptaene
  参考文献：
  名称：

  PYRIDOINDOLOBENZ[B,E]AZEPINE DERIVATIVES AND USES THEREOF

  摘要：

  本发明揭示了式1的pridoinolobenz [b，c] azepine衍生物，其中X为—O—，—S—，—SO—或—SO2—。 Y为单键或双键。 A和B独立地为—（CH2）n—; ‘n’从0到3变化。 R1至R9是各种电子给体、电子受体、亲水性或亲脂性基团，选取以优化式I化合物的物理化学和生物学性质。

  公开号：

  US20160039820A1

文献信息

• PYRIDOINDOLOBENZ[B,E]AZEPINE DERIVATIVES AND USES THEREOF
  申请人：Daya Drug Discoveries, Inc,

  公开号：US20160039820A1

  公开（公告）日：2016-02-11

  The present invention discloses pridoinolobenz[b,c]azepine derivatives of Formula 1, wherein X is —O—, —S—, —SO—, or —SO 2 —. Y is a single bond or a double bond. A and B are independently —(CH 2 ) n —; and ‘n’ varies from 0 to 3. R 1 to R 9 are various electron donating, electron withdrawing, hydrophilic, or lipophilic groups selected to optimize the physicochemical and biological properties of compounds of Formula I.

  本发明揭示了式1的pridoinolobenz [b，c] azepine衍生物，其中X为—O—，—S—，—SO—或—SO2—。 Y为单键或双键。 A和B独立地为—（CH2）n—; ‘n’从0到3变化。 R1至R9是各种电子给体、电子受体、亲水性或亲脂性基团，选取以优化式I化合物的物理化学和生物学性质。
• PENTACYCLIC PYRIDOINDOLO[B,E]AZEPINE DERIVATIVES AND USES THEREOF
  申请人：Daya CNS LLC

  公开号：EP2964331B1

  公开（公告）日：2019-08-28
• US9598414B2
  申请人：——

  公开号：US9598414B2

  公开（公告）日：2017-03-21
• [EN] PENTACYCLIC PYRIDOINDOLO[B,E]AZEPINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE PYRIDOINDOLO[B,E]AZÉPINE PENTACYCLIQUE ET LEURS UTILISATIONS
  申请人：DAYA DRUG DISCOVERIES INC

  公开号：WO2014137849A1

  公开（公告）日：2014-09-12

  The present invention discloses pyridoinolobenz[b,e]azepine derivatives of Formula 1,wherein X is -O-, -S-, -SO-, or -SO2-. Y is a single bond or a double bond. A and B are independently -(CH2)n-; and 'n' varies from 0 to 3. R1 to R9 are various electron donating, electron withdrawing, hydrophilic, or lipophilic groups selected to optimize the physicochemical and biological properties of compounds of Formula I.
• The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds
  作者：Raghavan Rajagopalan、Acintya Bandyopadhyaya、Desikan R. Rajagopalan、Parthasarathi Rajagopalan

  DOI：10.1016/j.bmcl.2013.12.024

  日期：2014.1

  Compounds 7, 8, and 9, derived from the novel scaffolds 3, 5, and 6, were synthesized and evaluated in vitro. The b, c -> c,d shift of the E-phenyl ring resulted in a large decrease (ca. 20- to 1000-fold) in binding to the 5-HT2A, 5-HT2C and H-2, receptors, and a modest decrease (ca. 10- to 20-fold) in binding to the 5-HT5A, D-2, D-5, and alpha(1D), receptors. The b, c -> d, e shift resulted in a large decrease in binding to the 5-HT1D, 5-HT2C, 5-HT6, and H-1 receptors, a modest decrease in binding to 5-HT1A, 5-HT5A and D2, D5, alpha(2B), and H2 receptors, and a large increase in affinity to the 5-HT3, 5-HT6, and sigma(1) receptors. (C) 2013 Elsevier Ltd. All rights reserved.